| [1] |
曹毛毛，陈万青. GLOBOCAN 2020全球癌症统计数据解读[J/CD].中国医学前沿杂志（电子版），2021，13（3）：63-69.
|
| [2] |
Shi JF, Wang L, Wu N, et al. Clinical characteristics and medical service utilization of lung cancer in China, 2005-2014: Overall design and results from a multicenter retrospective epidemiologic survey[J]. Lung Cancer, 2019, 128:91-100.
|
| [3] |
British Thoracic Society and Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party. BTS guidelines: Guidelines on the selection of patients with lung cancer for surgery[J]. Thorax, 2001, 56(2):89-108.
|
| [4] |
Port JL, Mirza FM, Lee PC, et al. Lobectomy in octogenarians with non-small cell lung cancer: Ramifications of increasing life expectancy and the benefits of minimally invasive surgery[J]. Ann Thorac Surg, 2011, 92(6):1951-1957.
|
| [5] |
Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group[J]. J Clin Oncol, 2008, 26(21):3552-3559.
|
| [6] |
NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data[J]. Lancet, 2014, 383(9928):1561-1571.
|
| [7] |
Houssaini MS, Damou M, Ismaili N. Advances in the management of non-small cell lung cancer (NSCLC): A new practice changing data from asco 2020 annual meeting[J]. Cancer Treat Res Commun, 2020, 25:100239.
|
| [8] |
Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(18):1711-1723.
|
| [9] |
Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer[J]. N Engl J Med, 2018, 378(21):1976-1986.
|
| [10] |
Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): An open-label, multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(11):1413-1422.
|
| [11] |
Halmos B, Burke T, Kalyvas C, et al. A matching-adjusted indirect comparison of pembrolizumab + chemotherapy vs. nivolumab + ipilimumab as first-line therapies in patients with PD-L1 TPS ≥1% metastatic NSCLC[J]. Cancers (Basel), 2020, 12(12):3648.
|
| [12] |
Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): An open-label, multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(11):1413-1422.
|
| [13] |
Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance[J]. Cell, 2008, 133(5):775-787.
|
| [14] |
陈思，赵泽锐，龙浩. 新辅助免疫治疗及联合化疗在NSCLC中的研究进展[J].中国肺癌杂志，2021，24（4）：284-292.
|
| [15] |
Fakiris AJ, Mcgarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study[J]. Int J Radiat Oncol Biol Phys, 2009, 75(3):677-682.
|
| [16] |
Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer[J]. JAMA, 2010, 303(11):1070-1076.
|
| [17] |
Senan S, Brade A, Wang LH, et al. PROCLAIM: Randomized phaseⅢ trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2016, 34(9):953-962.
|
| [18] |
Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stageⅢA orⅢB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study[J]. Lancet Oncol, 2015, 16(2):187-199.
|
| [19] |
Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stageⅠ non-small-cell lung cancer: can SBRT be comparable to surgery[J]? Int J Radiat Oncol Biol Phys, 2011, 81(5):1352-1358.
|
| [20] |
Xiao Y, Papiez L, Paulus R, et al. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: Stereotactic body radiotherapy of inoperable stageⅠ-Ⅱnon-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2009, 73(4):1235-1242.
|
| [21] |
Shinde A, Li R, Kim J, et al. Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly[J]. Semin Oncol, 2018, 45(4):210-219.
|
| [22] |
Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database[J]. J Clin Oncol, 2007, 25(35):5570-5577.
|
| [23] |
Mancini BR, Park HS, Harder EM, et al. Elderly patients undergoing SBRT for inoperable early-stage NSCLC achieve similar outcomes to younger patients[J]. Lung Cancer, 2016, 97:22-27.
|
| [24] |
任艳萍，焦玉新，戈伟强，等.立体定向放疗在高龄局限性肺癌患者中的疗效与安全性评估[J].老年医学与保健，2016，22（6）：387-390.
|
| [25] |
Veluswamy RR, Levy B, Wisnivesky JP. Chemotherapy in elderly patients with nonsmall cell lung cancer[J]. Curr Opin Pulm Med, 2016, 22(4):336-343.
|
| [26] |
Hinton S, Sandler A. Lung cancer in the elderly: Current and future chemotherapeutic options[J]. Drugs Aging, 2002, 19(5):365-375.
|
| [27] |
Langer CJ. Elderly patients with lung cancer: biases and evidence[J]. Curr Treat Options Oncol, 2002, 3(1):85-102.
|
| [28] |
Lilenbaum R. Management of advanced non-small-cell lung cancer in elderly populations[J]. Clin Lung Cancer, 2003, 5(3):169-173.
|
| [29] |
Chrischilles EA, Pendergast JF, Kahn KL, et al. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(4):620-627.
|
| [30] |
Karampeazis A, Vamvakas L, Kotsakis A, et al. Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced non-small cell lung cancer and use of a geriatric assessment: Lessons from a prematurely closed Hellenic Oncology Research Group randomized phaseⅢstudy[J]. J Geriatr Oncol, 2017, 8(1):23-30.
|
| [31] |
Kudoh S, Takeda K, Nakagawa K, et al. PhaseⅢstudy of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)[J]. J Clin Oncol, 2006, 24(22):3657-3663.
|
| [32] |
Losanno T, Gridelli C. Recent advances in targeted advanced lung cancer therapy in the elderly[J]. Expert Rev Anticancer Ther, 2017, 17(9):787-797.
|
| [33] |
Ohashi K, Takamori M, Takahashi Y, et al. Efficacy and safety of gefitinib as first-line chemotherapy for elderly patients with advanced non-small cell lung cancer (NSCLC)[J]. Gan To Kagaku Ryoho, 2019, 46(1):55-59.
|
| [34] |
Roviello G, Zanotti L, Cappelletti MR, et al. Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer[J]? Clin Exp Med, 2018, 18(1):15-20.
|
| [35] |
Furuta H, Uemura T, Yoshida T, et al. Efficacy and safety data of osimertinib in elderly patients with NSCLC who harbor the EGFR T790M mutation after failure of initial EGFR-TKI treatment[J]. Anticancer Res, 2018, 38(9):5231-5237.
|
| [36] |
Zhu J, Sharma DB, Gray SW, et al. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer[J]. JAMA, 2012, 307(15):1593-1601.
|
| [37] |
Aggarwal C, Langer CJ. Systemic therapy for elderly patients with non-small cell lung cancer: Where do we stand in 2019?[J]. Cancer, 2020, 126(5):931-934.
|
| [38] |
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2):123-135.
|
| [39] |
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17):1627-1639.
|
| [40] |
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial[J]. Lancet, 2016, 387(10027):1540-1550.
|
| [41] |
Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016, 387(10030):1837-1846.
|
| [42] |
Murray N, Turrisi AR. A review of first-line treatment for small-cell lung cancer[J]. J Thorac Oncol, 2006, 1(3):270-278.
|
| [43] |
Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: Current therapies and new targeted treatments[J]. Lancet, 2017, 389(10066):299-311.
|